Explore CEA CD3

Simultaneous binding of CEA on tumor cells and CD3 on T cells activates T cells, resulting in T-cell–mediated tumor killing

CEA: a tumor surface antigen

Carcinoembryonic antigen (CEA) is a cell-surface protein that mediates intracellular adhesion.1

  • CEA is expressed at low levels on the apical surface of normal epithelial tissues in a polarized expression pattern not accessible by therapeutic antibodies2
  • In cancer, CEA bridges healthy cells and tumor cells, which may play a role in metastasis3
  • CEA is highly expressed in multiple tumor types, including colorectal, gastric, pancreatic, non-small cell lung, breast, and other cancers1,4,5

CD3: a T-cell activator

CD3 (cluster of differentiation 3) is a multimeric protein composed of 4 subunits (γ, δ, ϵ, ζ), which are part of the T-cell receptor complex on the surface of T cells.6

  • Engagement of CD3 induces downstream signaling events that result in T-cell activation

Potential of simultaneous binding of CEA and CD3

Binding of a T-cell bispecific antibody to CEA on tumor cells and CD3 on T cells engages T cells and redirects their activity against tumor cells. T-cell activation—a result of the CEA-CD3 interaction—promotes the proliferation/expansion of pre-existing T cells and the recruitment of new T cells from the peripheral blood to the tumor microenvironment, which may further contribute to antitumor activity.2

  • In preclinical models, binding of T‑cell bispecific antibodies to CEA and CD3 induced tumor regression through T‑cell proliferation at tumor sites and recruitment of new T cells to the tumor bed7,8

References

Antibodies icon

Emerging development platforms

Discover our broad range of antitumor modalities.

Microscope icon

Discover cancer biomarkers

Learn more about the importance of cancer biomarkers.